23:56 , Feb 26, 2019 |  BC Extra  |  Company News

Management tracks: Immunomedics, Daiichi, Notable Labs

Immunomedics Inc. (NASDAQ:IMMU) said Michael Pehl resigned as president, CEO and a board member due to personal reasons, just 15 months after he joined the antibody-drug conjugate company. The news comes a month after FDA...
19:55 , Jul 13, 2018 |  BC Week In Review  |  Company News

Aquinox halves workforce after sole clinical asset misses in Phase III

Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP) said in an SEC filing it reduced headcount by 30 (53%) and halted all development of sole clinical asset rosiptor (AQX-1125) after the compound missed in a Phase III trial last...
03:04 , Jun 30, 2018 |  BioCentury  |  Finance

Eyes on launches

The annual summer slowdown isn’t restricted to just the stock market this year, as the clinical catalyst calendar also appears to be on holiday in 3Q18. Buysiders are therefore turning their attention to a spate...
14:46 , Jun 29, 2018 |  BC Week In Review  |  Clinical News

Aquinox discontinues development of rosiptor

Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP) said its sole clinical asset, rosiptor (AQX-1125), missed the primary endpoint in the double-blind, international Phase III LEADERSHIP 301 trial to treat interstitial cystitis/bladder pain syndrome (IC/BPS). The company said it...
19:06 , Jun 27, 2018 |  BC Extra  |  Clinical News

Aquinox halts product development, stock nosedives

Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP) plummeted $12.97 (85%) to $2.34 Wednesday after sole clinical asset rosiptor (AQX-1125) missed the primary endpoint in the Phase III LEADERSHIP 301 trial to treat interstitial cystitis/bladder pain syndrome (IC/BPS). The...
00:38 , Jan 6, 2018 |  BioCentury  |  Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to...
00:03 , Dec 16, 2017 |  BC Extra  |  Company News

Management tracks: Chugai, bioMérieux

Chugai Pharmaceutical Co. Ltd. (Tokyo:4519) said President and COO Tatsuro Kosaka will become president and CEO. He succeeds CEO Osamu Nagayama, who will remain chairman. Diagnostics company bioMérieux S.A. (Euronext:BIM) said Deputy CEO Alexandre Mérieux...
00:53 , Dec 31, 2016 |  BioCentury  |  Finance

Delivering takeouts

  BioCentury’s 25th annual Buyside View finds biotech investors focusing on mid-cap names with late-stage or marketed products that could become M&A targets. “The main theme playing at the moment is investors like us are...
07:00 , Oct 24, 2016 |  BC Week In Review  |  Clinical News

AQX-1125: Additional Phase II data

Additional data from the double-blind, North American Phase II LEADERSHIP 201 trial in 69 patients with moderate to severe BPS/IC pain showed that once-daily 200 mg oral AQX-1125 met the secondary endpoints of reducing 24-hour...
07:00 , Oct 4, 2016 |  BC Extra  |  Company News

Management tracks

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) named Brian McNamara CEO of its Consumer Healthcare division. He replaces Emma Walmsley, who is to succeed CEO Andrew Witty next year. McNamara is head of Europe & Americas in the...